Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Clinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...

Fear of a having a low blood sugar crash dissuades many people with Type 1 diabetes from getting the exercise they need, a ...

Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into ...